Merck's Q4 Beat vs. 2026 Guidance: What's Already Priced In?

The market's initial reaction to Merck's latest report was a classic case of focusing on the wrong signal. The company posted a clear quarterly beat, but the real story is in the guidance that followed. For the fourth quarter, Merck delivered adjusted profit of $2.04 per share, meeting analyst estimates, and revenue of $16.4 billion, topping the consensus. This strength was powered by robust demand for its flagship cancer drug, Keytruda, which saw sales of $8.37 billion for the quarter.

Yet the stock's rally appears to be priced for perfection, ignoring a more sobering outlook. For the full year 2026, management has guided to adjusted EPS of $5.00-$5.15 and revenue of $65.50B-$67.00B. Both figures fall significantly short of the Street's expectations, with the EPS guidance missing by nearly $0.60 and the revenue range's high end falling below the average analyst forecast. The disconnect is stark.

CEO Rob Davis has pointed to a specific, material headwind: the loss of patent exclusivity for key legacy products. He attributes the weaker-than-expected outlook directly to legacy products going off patent, specifically naming diabetes drugs Januvia and Janumet. This includes the impact of a new Medicare price for Januvia, which could hurt sales more than analysts had projected. The guidance, therefore, seems to be the more accurate reflection of near-term reality, while the Q4 beat was a snapshot of strength before the patent cliffs fully hit.

Assessing the Priced-In Headwinds

The market's rally on the Q4 beat has already priced in the near-term strength, but the guidance reveals a more complex picture of headwinds that are not yet fully reflected in the share price. Management's own actions, particularly the planned $3 billion in cost cuts by the end of 2027, signal they view these challenges as material and require a defensive response. The key question is whether the current valuation adequately discounts the specific, quantifiable pressures ahead.

One major headwind is the severe decline in Gardasil sales. In the fourth quarter, revenue for the HPV vaccine fell 35% year-over-year to $1.03 billion. The company has now assumed no Gardasil shipments to China in its 2026 full year guidance, a stark reversal from previous expectations. This is a direct, quantifiable revenue loss that the market may be underestimating. The guidance itself acknowledges this as a "manageable impact," but the scale of the sales drop suggests it is a significant drag on growth for the year.

A longer-term pressure point looms on the horizon: the loss of patent protection for Keytruda. While the drug's sales are still strong, Keytruda's patents are expected to start expiring in 2028. This creates a multi-year revenue pressure point that is not yet captured in the 2026 numbers. The company is already preparing for this by pushing a new, faster formulation, Keytruda Qlex, which had $35 million in US sales last quarter. The fact that management is investing in such a strategic shift underscores the materiality of the future generic threat.

The Strategic Counterweights and Valuation

The market's focus on Merck's Q4 beat has overshadowed the more critical narrative: the company is navigating a period of significant transition. While the guidance sets a lower baseline for 2026, there are strategic counterweights that could eventually support the valuation. The key question is whether these positives are already priced in, or if the stock still offers a margin of safety given the known headwinds.

On the growth side, new acquisitions are showing early promise. The $10 billion purchase of Verona Pharma last year brought in Ohtuvayre, which beat expectations and has been described as having "multi-billion dollar" commercial potential. Similarly, the pneumonia vaccine Capvaxive and the lung disease drug Winrevair are outperforming estimates. These products helped Merck beat Q4 revenue expectations and provide a pipeline of future growth. However, they are not yet material to the 2026 outlook, which is dominated by the legacy product declines. The strategic moves, including the planned $3 billion in cost cuts, are aimed at funding this transition and mitigating the impact of the patent cliffs.

Valuation tells a story of a stock that has already rallied on the Q4 news. Merck's shares are up 32.16% in the last three months, a move that appears to have priced in the quarterly beat and the initial promise of new products. This surge suggests the market is looking past the guidance miss, perhaps viewing the beat as a sign of underlying operational strength. Yet the guidance itself-the lower EPS and revenue targets-may now be the new baseline for the year. The stock's recent run-up could be seen as a classic "buy the rumor, sell the news" dynamic, where the positive Q4 result was the rumor, and the sobering outlook is the news.

The consensus view has been adjusting downward, with the company seeing 14 negative EPS revisions in the last 90 days. This reflects a gradual acceptance of the headwinds. However, the full impact of the patent cliffs-both for Gardasil and, more significantly, for Keytruda starting in 2028-may still be underestimated. The market is discounting near-term pain, but the longer-term revenue pressure from generic competition remains a structural risk that is not yet fully reflected in the current price. The bottom line is that while Merck has promising new assets and a defensive cost program, the stock's recent performance suggests much of the near-term optimism is already baked in. The risk/reward now hinges on execution and whether the company can successfully ramp these new products fast enough to offset the known declines.

Catalysts and Risks: What to Watch

The path forward for Merck is now defined by a series of near-term catalysts and risks that will test the market's current optimism. The stock's recent rally suggests much of the Q4 beat is priced in, but the real story will be in the execution against the sobering 2026 guidance. Investors must monitor specific data points to gauge whether the company can stabilize its core products or if the headwinds are more severe than management has indicated.

The most immediate watchpoint is the performance of Gardasil and Keytruda in the first quarter. For Gardasil, the key will be whether the 35% year-over-year decline in fourth-quarter sales continues or shows signs of stabilization. The company has assumed no shipments to China in its 2026 guidance, a major market. Any update on the China situation or the impact of the new U.S. dosing recommendation will be critical. CEO Rob Davis has called the U.S. policy impact "manageable," but persistent weakness in this segment could signal broader challenges for the vaccine portfolio.

For Keytruda, the focus shifts to maintaining its blockbuster momentum. While sales of $8.37 billion last quarter were strong, the drug's patents are expected to start expiring in 2028. The first quarter will provide a baseline for its performance before the looming generic threat. Any deceleration in growth here would directly challenge the company's ability to fund its transition through new products and cost cuts.

The primary risk is that the market underestimates the combined impact of multiple patent expirations and persistent Gardasil weakness. The guidance already accounts for the loss of exclusivity for diabetes drugs Januvia and Janumet, but the $3 billion cost-cutting program by the end of 2027 underscores the scale of the challenge. If Gardasil remains weak and Keytruda's patent cliff materializes sooner than expected, the company may need to accelerate its defensive actions, potentially pressuring margins further. The risk/reward asymmetry hinges on whether these known pressures will crystallize faster than anticipated, creating a gap between the current valuation and the new, lower growth trajectory.